FDA Approves Veklury (Remdesivir) To Treat COVID-19 In People With Mild To Severe Hepatic Impairment With No Dose Adjustment
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Veklury (Remdesivir), a drug developed by Gilead Sciences, Inc. (GILD), to treat COVID-19 in people with mild to severe hepatic impairment without any dose adjustment.
August 24, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's approval of Gilead's Veklury (Remdesivir) for a new patient group could potentially increase the drug's sales, positively impacting Gilead's revenues.
The FDA's approval expands the potential market for Veklury, which could lead to increased sales and revenues for Gilead. This is likely to have a positive impact on Gilead's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100